Disability RMS Revenue and Competitors

South Portland, ME USA

Location

N/A

Total Funding

Insurance

Industry

Estimated Revenue & Valuation

  • Disability RMS's estimated annual revenue is currently $72.6M per year.(i)
  • Disability RMS's estimated revenue per employee is $286,957

Employee Data

  • Disability RMS has 253 Employees.(i)
  • Disability RMS grew their employee count by 3% last year.

Disability RMS's People

NameTitleEmail/Phone
1
VP, CFOReveal Email/Phone
2
CIOReveal Email/Phone
3
PresidentReveal Email/Phone
4
Managed Disability AnalystReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13310M114163%$3.2MN/A
#2
$88.8M323N/AN/AN/A
#3
$10.7M440%N/AN/A
#4
$6.2M359%N/AN/A
#5
$34.6M143N/AN/AN/A
#6
$8.4M489%N/AN/A
#7
$260.3M7265%N/AN/A
#8
$12.9M6115%N/AN/A
#9
$6.5M25-17%N/AN/A
#10
$10.1M51-14%N/AN/A
Add Company

What Is Disability RMS?

Disability RMS is the nation’s leading provider of turnkey disability risk management products and services. We offer unparalleled Actuarial, Underwriting and Claims industry expertise in risk management. \n\nOur team consists of more than 350 highly skilled professionals with the specialized product knowledge and service skills required to succeed in today’s complex risk protection market. The cohesiveness, experience, and dedication of our team enables us to provide the highest levels of service and innovation in the industry.

keywords:N/A

N/A

Total Funding

253

Number of Employees

$72.6M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Disability RMS News

2022-04-20 - #AAN2022 - More MS Patients Relapse-free With Ublituximab ...

... impact on the accumulation of disability,” Lawrence Steinman, MD, ... II Studies in Patients With Relapsing Multiple Sclerosis (RMS).”.

2022-03-30 - New Data for Genentech's Ocrevus (ocrelizumab) Show ...

“We are encouraged by the low levels of disability progression and ... Ocrevus is the first and only therapy approved for relapsing MS (RMS;...

2022-03-30 - TG Therapeutics Announces Data Presentations from the ...

Poster Presentation Title:Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$126.6M3044%N/A
#2
$135.3M3234%N/A
#3
$109M323-5%N/A
#4
$90.6M34523%N/A
#5
$189.3M4914%N/A